Tag:
Bayer
Latest Headlines
Latest Headlines
Bayer bucks pharma trend with 'remarkable' growth in new drugs
Bayer's new drugs are bringing home the bacon. The German drugmaker raised its 2015 forecast for 5 key products to €2.5 billion ($3.3 billion)--and confirmed previous promises that those drugs would surpass €5.5 billion by 2020.
Bayer wins new use for fast-moving cancer drug Stivarga
Bayer's new cancer drug Stivarga has already added a notch to its belt. Cleared by the FDA last year to treat colorectal cancer, the drug is now approved as a treatment for a rare form of gastric cancer, gastrointestinal stromal tumors.
Study: ED drugmakers aren't properly policing their TV ads
Embarrassed by the ads for erectile dysfunction drugs that pop up at the most inopportune moments? A new study found that the television commercials are indeed airing at family-viewing times--contrary to drugmakers' express promises to refrain.
Bayer, Algeta nab priority review for prostate cancer drug
In-licensed from Norway's Algeta, Alpharadin is one of the pharma company's top late-stage prospects, following a string of regulatory wins on the development front.
European drug discovery platform emerges in €196M effort
Europe's pharma community is revving up a drug discovery engine. A new effort involving 30 partners--including Bayer, Johnson & Johnson's Janssen and 5 other large pharmas--has launched to spark discovery of new treatments, using a crowdsourcing and open-innovation approach.
Bayer hands off FDA app as pulmonary hypertension drug race heats up
Bayer has raced to the FDA with its application for riociguat, a promising candidate for pulmonary hypertension and a key player in the pharma giant's plans for a blockbuster year in 2013 as it sets the stage for a high-profile market battle with two big competitors.
EU's biggest drugmakers team up in €196M discovery effort
Seven major European drugmakers joined with other pharma companies, academics and other collaborators in a €196 million ($262.6 million) project to share and screen hundreds of thousands of compounds. Report
7 major pharmas unite with academics in €196M discovery effort
Europe's pharma community is revving up a drug-discovery engine. A new effort involving 30 partners--including Bayer, Johnson & Johnson's Janssen and 5 other large pharmas--has launched to spark discovery of new treatments, using a crowd-sourcing and open innovation approach.
Fight for anticoagulant market heats up with antidote deals
What would top Xarelto for Bayer and Johnson & Johnson? Xarelto with an easy antidote.
France yanking Bayer's Diane-35 off the market
France's drug regulators last year faced scathing criticism for dragging their feet when it came to the dangers of off-label use of diabetes drug Mediator. Now faced with consumer fears over deaths tied to off-label use of Bayer acne drug, Diane-35, they are acting with dispatch.
